CL2019000229A1 - Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida. - Google Patents
Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida.Info
- Publication number
- CL2019000229A1 CL2019000229A1 CL2019000229A CL2019000229A CL2019000229A1 CL 2019000229 A1 CL2019000229 A1 CL 2019000229A1 CL 2019000229 A CL2019000229 A CL 2019000229A CL 2019000229 A CL2019000229 A CL 2019000229A CL 2019000229 A1 CL2019000229 A1 CL 2019000229A1
- Authority
- CL
- Chile
- Prior art keywords
- bis
- new use
- mercaptoethyl isophthalamide
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201613535 | 2016-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000229A1 true CL2019000229A1 (es) | 2019-04-26 |
Family
ID=60202272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000229A CL2019000229A1 (es) | 2016-08-05 | 2019-01-29 | Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida. |
Country Status (30)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005057D0 (en) | 2020-04-06 | 2020-05-20 | Emeramed Ltd | New Use |
| WO2026037909A1 (en) * | 2024-08-16 | 2026-02-19 | Emeramed Limited | N,n-bis-2-mercaptoethyl isophthalamide for use in the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586600B2 (en) | 2000-12-06 | 2003-07-01 | University Of Kentucky Research Foundation | Multidentate sulfur-containing ligands |
| US8950583B2 (en) * | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| US20120122787A1 (en) * | 2009-07-10 | 2012-05-17 | Rong Li | Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases |
| JP2013505963A (ja) | 2009-09-28 | 2013-02-21 | ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデイション | 汚染された環境から元素を除去するチオール含有化合物およびその使用方法 |
| US8575218B2 (en) | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| US20110237776A1 (en) | 2010-03-25 | 2011-09-29 | Haley Boyd E | Aromatic compounds with sulfur containing ligands |
| US8426368B2 (en) | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
-
2017
- 2017-08-04 LT LTEPPCT/GB2017/052306T patent/LT3493849T/lt unknown
- 2017-08-04 HU HUE17793720A patent/HUE057782T2/hu unknown
- 2017-08-04 EP EP21211493.8A patent/EP4029497A1/en not_active Withdrawn
- 2017-08-04 CN CN202511855908.5A patent/CN121926911A/zh active Pending
- 2017-08-04 MX MX2019000978A patent/MX387853B/es unknown
- 2017-08-04 WO PCT/GB2017/052306 patent/WO2018025049A1/en not_active Ceased
- 2017-08-04 ES ES17793720T patent/ES2907838T3/es active Active
- 2017-08-04 SI SI201731094T patent/SI3493849T1/sl unknown
- 2017-08-04 SM SM20220109T patent/SMT202200109T1/it unknown
- 2017-08-04 BR BR112019002130-2A patent/BR112019002130A2/pt not_active Application Discontinuation
- 2017-08-04 PL PL17793720T patent/PL3493849T3/pl unknown
- 2017-08-04 DK DK17793720.8T patent/DK3493849T3/da active
- 2017-08-04 RS RS20220147A patent/RS62924B1/sr unknown
- 2017-08-04 MD MDE20190671T patent/MD3493849T2/ro unknown
- 2017-08-04 CN CN201780046065.1A patent/CN109562179A/zh active Pending
- 2017-08-04 JP JP2019505490A patent/JP6926192B2/ja active Active
- 2017-08-04 KR KR1020197003227A patent/KR102538388B1/ko active Active
- 2017-08-04 HR HRP20220252TT patent/HRP20220252T1/hr unknown
- 2017-08-04 PT PT177937208T patent/PT3493849T/pt unknown
- 2017-08-04 MA MA45855A patent/MA45855B1/fr unknown
- 2017-08-04 EA EA201990443A patent/EA201990443A1/ru unknown
- 2017-08-04 AU AU2017305661A patent/AU2017305661B2/en active Active
- 2017-08-04 US US16/318,842 patent/US20190240173A1/en not_active Abandoned
- 2017-08-04 EP EP17793720.8A patent/EP3493849B1/en active Active
- 2017-08-04 SG SG11201900565RA patent/SG11201900565RA/en unknown
- 2017-08-04 UA UAA201902172A patent/UA125394C2/uk unknown
- 2017-08-04 MY MYPI2019000127A patent/MY199733A/en unknown
-
2019
- 2019-01-28 ZA ZA2019/00594A patent/ZA201900594B/en unknown
- 2019-01-29 CL CL2019000229A patent/CL2019000229A1/es unknown
- 2019-01-29 IL IL264538A patent/IL264538B2/en unknown
- 2019-02-01 PH PH12019500237A patent/PH12019500237A1/en unknown
-
2022
- 2022-03-01 CY CY20221100175T patent/CY1125039T1/el unknown
-
2024
- 2024-12-06 US US18/972,315 patent/US20250325503A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000978A1 (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| DOP2017000178A (es) | Inhibidores selectivos de bace1 | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| MX2017009449A (es) | Inhibidor jak. | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MX2016016534A (es) | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| CL2019000857A1 (es) | Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas. | |
| BR112016017620A2 (pt) | Composto esteroidal para uso no tratamento da encefalopatia hepática | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| CL2017001904A1 (es) | Composición para el tratamiento de enfermedad veno-oclusiva hepática. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| CL2017001276A1 (es) | Derivados de benzotiazol antibacterianos | |
| CY1125039T1 (el) | Νεα χρηση του ν,ν-δις-2-μερκαπτοαιθυλ ισοφθαλαμιδιου | |
| GB2543709A (en) | Pharmaceutical agent | |
| AR104241A1 (es) | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |